Background
==========

Gliomas are one of the most common malignant tumors of the central nervous system. Gliomas represent a group of low grade and high grade brain tumors that originate from glial cells. Most are characterized by diffuse infiltrative growth in the surrounding brain. According to the 2007 WHO grading system \[[@B1]\], these tumors are classified as typical WHO grade I-IV. The median survival for patients with anaplastic astrocytoma (WHO grade III) and glioblastoma (WHO grade IV) is less than threes years and less than one year, respectively \[[@B2]\]. The prognosis remains poor despite extensive research and advances in radiation therapy and chemotherapeutic regimes \[[@B3]\]. All types of cancer as well as glioma constitute a major public health problem that presents several challenges to researchers such as identification of biomarkers for improved and early diagnosis, classification of tumors, and the definition of targets for more effective treatment. Genetic analysis over the past 30 years has defined the major mutational targets in the human genome that are associated with the formation of glioma \[[@B4]\]. Moreover, large-scale association genome-wide surveys have been used to identify new biomarkers that have been developed as diagnostic and prognostic tools.

In this study, to unravel molecular glioma tumorigenesis and discover novel molecular biomarkers for diagnostic and/or prognostic purposes, we apply WebArrayDB software (<http://www.WebArrayDB.org>) to span platform integrate and analyze the microarray datasets \[[@B5]-[@B7]\], including data stored at the Cancer Genome Anatomy Project (<http://cgap.nci.nih.gov/Genes>).

Among the genes up-regulated in gliomas, we focused on a subset of the significantly up-regulated genes, the minichromosome maintenance (MCM) family. The MCM family includes eight members: MCM2-MCM7 and MCM10 \[[@B8]\]. They are considered to function as licensing components for the S-phase of cell cycle \[[@B9]\]. MCMs can be expressed in abundance in different cell cycles and degraded in quiescence, senescence and differentiation steps thus they can be used as specific markers of the cell cycle state in tissues \[[@B10]\]. This feature of MCM genes in proliferating cells has led to their potential clinical application as a marker for cancer screening \[[@B11]\].

Here we report that MCM family genes are almost up-regulated in 59 human glioma tumor samples compared to six normal brain controls by qRT-PCR. Our study indicates for the first time that high MCM2 mRNA expression appears to be strongly associated with poor overall survival in high grade glioma. Furthermore, we report that MCM7 is strongly correlated with patient outcome in WHO grade II-IV. MCM3 expression found to be up-regulated in glioma and correlated with overall survival in WHO grade III. MCM2, MCM3 and MCM7 expression level were of greater prognostic relevance than histological diagnosis according to the current WHO classification system. Interestingly, in the last few years, studies have pointed out the roles of MCM family members as diagnostic and prognostic markers for several malignancies \[[@B12]\].

Methods
=======

Patients and tumor samples
--------------------------

A total of 59 glioma specimens were obtained from the Department of Neurosurgery, First Affiliated Hospital of Jilin University, from 2003 to 2012. The samples included 21 females and 38 males and an age range 2--69 years. Samples were collected immediately after surgical resection, snap frozen, and stored at -80°C until used for RNA extraction. All gliomas were samples of primary tumor before therapy. All cases had been diagnosed at the primary hospital by neuropathologists. Original pathology slides were obtained and reviewed blinded to the original diagnosis according to the 2007 WHO classification (14 II grade, 21 III grade and 24 IV grade). The samples consisted of astrocytoma (n = 27), anaplastic astrocytoma (n = 9) and glioblastoma (n = 23). Six control samples (normal brain) were obtained from the Department of Neurosurgery, First Affiliated Hospital of Jilin University from patients undergoing surgery for brain trauma (n = 4) and epilepsy (n = 2). They were all reviewed to verify the absence of tumor. Written informed consent for participation in the study was obtained from all participants or their guardians. The study was approved by the Institutional Review Board (IRB) of The First Hospital of Jilin University (IRB00008484).

RNA isolation and quality evaluation
------------------------------------

Total RNA was extracted from frozen sections with the TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocol. Total RNA yield was measured with an A260/280 ratio of 1.7-1.9, demonstrating purity. Quality was evaluated on nanochips with the Bio-Rad Experion automated electrophoresis system (Bio-Rad Laboratories, Hercules, CA, USA). Samples had a 28S/18S ratio of 1.5 and did not show evidence of ribosomal peak degradation.

Real-time quantitative reverse transcription PCR
------------------------------------------------

About 500 ng total RNA from each sample was reverse transcribed with SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). Primers were designed with AlleleID Version 7.0 software (Premierbiosoft, Palo Alto, CA, USA). Predesigned gene expression assays were obtained from Integrated Device Technology (IDT, San Diego, CA, USA). Real-time quantitative PCR was then carried out using an ABI Prism 7900 Sequence Detection System (Applied Biosystems, Carlsbad, CA, USA). A quantity of 15 ng of cDNA was used in a 25 μl PCR reaction containing the appropriate primers and 1 × SYBR Green PCR Super mix (BioPioneer, San Diego, CA, USA). All products were 77 to 134 bp. Dissociation curves of each sample were used to check the specificity of amplification. PCR reactions were examined by 1.6% agarose gel electrophoresis for verification of dissociation curve results. Parallel experiments were carried out using an 18S rRNA and HPRT1 primer set. qPCR reactions were performed in triplicate, and the relative fold changes were calculated with the Pfaffl method \[[@B13]\] for each gene corrected using 18S rRNA + HPRT1\[[@B14]\]. All primer pairs utilized in this study presented amplification efficiency between 91-110% (Additional file [1](#S1){ref-type="supplementary-material"}).

Western blot
------------

To detect MCM2, MCM3 and MCM7 protein in glioma tumors, we examined six glioma samples (two each of WHO stages II, III, IV). The protein concentration of cell lysates was determined by the Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer's instructions. Thirty micrograms of protein per tissue lysate was electrophoresed on 7-12% gels and transferred to a polyvinylidene difluoride membrane filter (Millipore, Billerica, MA, USA). Blots were probed with the appropriate antibody. Quantitative determination of the protein was assessed by densitometric scanning of the band from film. An AlphaImager 2000 Documentation and Analysis System (Alpha Innotech Corp, San Leandro, CA, USA) was used to quantify bands of appropriate sizes.

The following primary antibodies were used: anti-*β*-actin (Sigma Chemical Co, St. Louis MO, USA), anti-MCM2 (sc-10771, Santa Cruz Biotechnology, USA), anti-MCM3 (sc-9849, Santa Cruz Biotechnology, USA), and anti-MCM7 (sc-22782, Santa Cruz Biotechnology, USA).

Statistical analysis
--------------------

The statistical significance of differences in the means was calculated using the ANVOA test. To identify a model describing the relationship between survival and the MCMs mRNA expression, the functional form of the relationship was tested by maximally selected log-rank statistics as previously described \[[@B15]\]. The resulting model was applied in further survival analyses. Multivariate Cox regression was used to investigate the prognostic power of candidate gene expression adjusting for established prognostic variables. The Cox proportional hazards regression were carried out with the use of the design and survival package of the R software environment. Overall survival curves (from diagnosis to death) were obtained using the Kaplan-Meier method and compared with a log-rank test. A *p* value of less than 0.05 was considered to indicate statistical significance.

Results
=======

Up-regulation of the MCM family expression in human glioma samples
------------------------------------------------------------------

The mRNA expression level of the MCM family members were examined in 59 human glioma samples and six normal brain tissues by qPCR (n = 3), normalized to 18S rRNA and HPRT1 levels. We found a significant increase in MCM2 (3.5 fold), MCM3 (3.1 fold), MCM4 (4.3 fold), MCM5 (3.8 fold), MCM6 (3.5 fold), MCM7 (3.0 fold) and MCM10 (3.6 fold) expressions in tumor tissues (the average fold value of three grades) compared to the normal brain controls. Moreover, as shown in Table [1](#T1){ref-type="table"}, we observed that MCM3-MCM5,MCM7 and MCM10 were significantly changed between grade II, III and IV samples (*p* \< 0.05). MCM2 and MCM6 were significantly increased between grade II (low grade) and III-IV (high grade) samples (*p* \< 0.05). Four independent external microarray datasets (8 normal, 29 stage II, 116 stage III and 618 stage IV, Additional file [2](#S2){ref-type="supplementary-material"}) were analyzed using the WebArrayDB cross-platform analysis suite to validate our experiment results. Genes were sorted in ascending order according to the *p* values for WHO grade, after taking into account gender and patient age as variables. Expression of MCM family members was highly correlated with glioma grade (Table [1](#T1){ref-type="table"}). To confirm the specificity of the qPCR results, we characterized MCM2, MCM3, MCM7, as well as *β*-actin as a loading control, in six glioma samples for which freshly frozen materials were available. As shown in Figure [1](#F1){ref-type="fig"}, an immunoreactive band of MCM2, MCM3 and MCM7 were seen in all six cases of gliomas, MCM2, MCM3 and MCM7 expressions were significantly higher in malignant tissues than in tissues with low malignant potential.

###### 

Comparison of mRNA expression of MCMs in glioma tumor tissue by qRT-PCR and microarray analysis

    **Gene**    **Unique ID**   **Gene origin**   **Fold**   ***p*value**                                                                                                        
  ------------ --------------- ----------------- ---------- -------------- ------ ------ ------ ------------ ---------- ---------- ---------- ------------ ---------- ---------- ----------
      MCM2      202107_s\_at        qRT-PCR         1.91         3.9        4.22   2.04   2.21      1.08        3.5      1.27E-02   1.38E-04    5.43E-10    1.20E-04   4.91E-10   3.84E-01
   Microarray       1.61             3.68           5.39         2.16       3.16   1.47           2.84E-02    5.22E-05   8.61E-09   5.33E-09   0.00E + 00   1.53E-05             
      MCM3        201555_at         qRT-PCR         1.59         3.01       4.46   1.89   2.81      1.49        3.1      1.08E-01   2.51E-02    8.25E-10    2.00E-02   1.46E-11   3.86E-03
   Microarray       1.92             2.32           2.79         1.26       1.52   1.2            1.57E-02    1.14E-04   2.45E-07   3.24E-02    1.18E-07    3.26E-03             
      MCM4      222036_s\_at        qRT-PCR         2.41         4.56       6.15   1.89   2.55      1.35        4.3      1.14E-03   2.42E-04    2.11E-06    6.07E-04   2.33E-07   2.81E-02
   Microarray       0.81             1.51           1.61         1.58       1.69   1.07          1.00E + 00   5.07E-01   2.01E-01   9.64E-06    6.36E-09    7.04E-01             
      MCM5        201755_at         qRT-PCR         1.91         4.25       4.48   2.22   2.34      1.05        3.8      1.49E-02   2.38E-04    5.92E-07    3.32E-05   1.49E-02   1.43E-02
   Microarray       0.57             1.95           2.46         2.03       2.57   1.26           7.88E-01    5.97E-01   1.14E-01   1.19E-04    7.13E-10    1.23E-01             
      MCM6        201930_at         qRT-PCR         1.28         4.8        4.63   3.76   3.62      0.96        3.5      4.46E-01   4.46E-05    8.26E-09    2.65E-07   6.85E-12   7.04E-01
   Microarray       2.24             2.63           3.05         2.07       2.4    1.16           2.82E-03    1.83E-02   3.22E-02   4.30E-13   0.00E + 00   7.39E-02             
      MCM7      208795_s\_at        qRT-PCR         1.51         3.29       4.33   2.17   2.86      1.32        3.0      3.39E-01   1.82E-02    1.34E-08    1.25E-02   5.59E-09   4.95E-02
   Microarray       1.02             2.23           2.08         1.79       1.67   0.93          1.00E + 00   8.94E-04   1.93E-03   5.57E-10    6.93E-10    6.36E-01             
     MCM10      220651_s\_at        qRT-PCR         2.58         3.86       4.73   1.5    1.83      1.22        3.6      5.72E-05   3.31E-04    3.20E-08    8.96E-03   4.41E-07   6.48E-02
   Microarray       6.18             26.21         31.81         3.54       4.29   1.21           1.46E-02    6.54E-09   3.05E-10   4.62E-07    1.77E-11    5.83E-01             

MCM3 and MCM5,MCM7 and MCM10 were significant different between grade II, III and IV samples (*p* \< 0.05). MCM2 and MCM6 expressions were significantly increased between grade II (low grade) and III-IV (high grade) samples (*p* \< 0.05).

![**Expression of MCM2, MCM3 and MCM7 protein in gliomas by Western blot. A** western blots of six glioma samples (WHO grade II, III and IV). **B** Quantitation of the western blots by using *β*-actin as the loading control.](1471-2407-14-526-1){#F1}

Multivariate survival analysis of prognostic parameters
-------------------------------------------------------

Multivariate survival analysis identified high expression of MCM2 as an independent prognostic factor for survival time, as well as MCM3 and MCM7 (*p* \< 0.05), (Table [2](#T2){ref-type="table"}).

###### 

Multivariate analysis on prognosis of the patients (n = 59)

   **Parameter**   **Risk ratio**    **95% CI**    ***p***
  --------------- ---------------- -------------- ---------
        Sex            2.067        0.789-4.670     0.151
     Age (≥40)         3.155        1.984-4.039     0.042
   WHO (Grade 4)       3.0843       1.523-3.810     0.034
       MCM2            8.519        6.280-10.508    0.004
       MCM3            7.328        5.102-9.833     0.007
       MCM4            0.506        0.843-1.441     0.477
       MCM5            2.117        0.946-3.127     0.146
       MCM6            2.873        1.377-4.073     0.090
       MCM7            6.576        4.114-8.243     0.010
       MCM10           0.029        0.015-1.093     0.937

The MCMs expression correlates with poor outcome in patients with glioma
------------------------------------------------------------------------

We reviewed each grade of tumor separately and investigated whether the expression of MCM2, MCM3 and MCM7 predicts patient survival within each subgroup. The search for a model describing the relationship between survival and expression of MCM family genes expression using maximally selected log-rank statistics identified a cutoff model to be most suitable: MCM2 (fold change cutoff for stage II 2.3, III 4.7, and IV 5.6,), MCM3(II 2.4, III 3.1, and IV 5.3) and MCM7 (II 1.6, III 4.6, and IV 6.1). The qPCR cutoff ratios were used to separate two patient subgroups with significantly different outcomes \[maximally selected log rank statistics, *p* \< 0.05 (overall survival)\]. Applying these MCM family expression cutoff to Kaplan-Meier survival curve estimation revealed decreased survival probability for patients with tumor expressing high levels of MCM2, MCM3 and MCM7 (*p* \< 0.05), (Figure [2](#F2){ref-type="fig"}). In the grade II group, MCM7 expression appeared to be a strongly positive prognostic factor (*p* \< 0.01). In the grade III group, better prognosis was found for patients with glioma with low expression of three genes compared to patients with high expression (*p* \< 0.01). MCM2 and MCM7 expression appeared to be prognostic factors in the grade IV group, although they are not strongly positive in any of these cases (*p* \< 0.05). Thus the expression level of MCM2, MCM3 and MCM7 reveal information on the survival probability for patients with glioma beyond that revealed by grade alone.

![**Kaplan-Meier estimates of overall survival (OS) in relation to MCM2, MCM3 and MCM7 expression as determined by qPCR.** Cutoff value for dichotomization of MCM2, MCM3 and MCM7 expression and *p* values were determined by maximally selected log-rank statistics. **A** High MCM2 expression appeared to be strongly associated with poor overall survival in high grade glioma. **B** MCM3 expression was to be up-regulated in glioma and correlated with OS in the grade III group, In the grade III group, the expression of three genes was significantly associated with patient outcome (*p* \< 0.01); **C** MCM7 expression appeared to be a strongly positive prognostic factor in the WHO grade II-IV group (*p* \< 0.01).](1471-2407-14-526-2){#F2}

The result was validated by GBM database. Repository of Molecular Brain Neoplasia Data (Rembrandt, <https://caintegrator.nci.nih.gov/rembrandt/>), a cancer clinical genomics database and a Web-based data mining and analysis platform aimed at facilitating discovery by connecting the dots between clinical information and genomic characterization data. The microarray data are available for 181 GBM samples in Rembrandt database. MCM2 and MCM3 were not correlate with the prognosis of GBM patients (*p* \> 0.05). When the cut-off point was the up-regulation of 2 fold, MCM7 was significant relative to the outcome of GBM patients (*p* \< 0.01), (Table [3](#T3){ref-type="table"}).

###### 

**Comparison of mRNA expression of MCM2, MCM3 and MCM7 in glioma tumor tissue by microarray analysis (Rembrandt,**<https://caintegrator.nci.nih.gov/rembrandt/>**)**

   **Gene**   **Unique ID**   **Gene origin**   **Number of samples (all upregulate)**   **Fold**   ***p*value**  
  ---------- --------------- ----------------- ---------------------------------------- ---------- -------------- -------
     MCM2     202107_s\_at      Microarray                       133                        48          2.0        0.181
     MCM3       201555_at       Microarray                       138                        43          2.0        0.417
     MCM7     208795_s\_at      Microarray                        59                       122          3.0        0.009

*p* \< 0.05.

MCM2 and MCM3 were not correlate with the prognosis of GBM patients (*p* \> 0.05). When the cutoff point was the up-regulation of 3fold, MCM7 was significant correlate with the outcome of GBM patients (*p* \< 0.01).

Discussion
==========

Glioma tumors are the most common and deadly brain tumors. However, the survival of patients with low grade (stage II) glioma is significantly higher than that of patients with high grade (stage III-IV) tumors. In the study, we applied WebArrayDB software (<http://www.WebArrayDB.org>) to analysis three independent microarray datasets which come from different microarray platforms. We focused on the part of the members of the MCM gene family most highly significantly up-regulated in gliomas.

MCMs were first discovered in the mutants of the yeast Saccharomyces cerevisiae that had defects in maintaining a simple minichromosome \[[@B16]\]. MCM 2--7 form a heterohexamer complex \[[@B17]\]. The MCM protein complex is associated with the origins of DNA replication to form part of the pre-replicative complex. Activation of MCM complex by cyclin-dependent kinases, such as Cdc6, Cdt1 andDbf4/Cdc7, leads to initiation of DNA synthesis \[[@B18]\]. The hexameric MCM component of the pre-replicative complex exhibits helicase activity that may make DNA unwind during replication \[[@B11]\]. Thus, MCM proteins allow the DNA replication machinery to access binding sites on DNA \[[@B19]\]. Several studies suggested that increased levels of MCMs can identify not only malignant cells \[[@B20]-[@B25]\] but also precancerous cells and tumor recurrence \[[@B26]-[@B28]\], indicating that they might also serve as prognostic tumor markers. The last member, MCM10, may have a dual function: firstly to stabilize DNA polymerase-α-primase and secondly to target it to chromatin \[[@B29]\].

Recent studies have proven that MCMs expression has a relationship with diagnosis and prognosis. MCM2 and MCM3 seem to have the most important role in several types of neoplasia, including alimentary system tumors \[[@B30]-[@B35]\], genitourinary system tumors \[[@B36]-[@B41]\], lung cancer \[[@B42],[@B43]\], breast cancer \[[@B44]-[@B47]\], and meningioma \[[@B27],[@B48]\]. Moreover, several investigators have found that the measurement of MCM6 protein expression is a good diagnostic marker for chondrosarcoma \[[@B49]\], and lymphoma \[[@B50]\]. MCM2, MCM3 and MCM7 proteins expression is also known to be an important tool for estimating tumor proliferation and a useful adjunct to the routinely used proliferation markers for glioma diagnosis \[[@B51]-[@B56]\].

Moreover, in past research, MCMs have also provided useful information on outcome of patients with glioma. Wharton *et al*. found that cases with a high MCM2 labeling index had a poorer prognosis than those with a low index in patients with oligodendroglioma \[[@B51]\]. Scott *et al*. reported that the cyclin A:MCM2 labeling fraction might predict a relatively favorable response to radical radiotherapy in patients with glioblastoma \[[@B52]\]. Söling *et al*. in their series of patients with astrocytoma found that high MCM3 expression is an independent predictor of poor outcome \[[@B53]\].

Compared with previous reports, we confirmed MCM 2, MCM 3 and MCM7 expression were correlated with WHO grading of glioma tumors on mRNA profiles by microarray data analysis and qPCR. The result of western blot also validated this finding. Some studies reported positive correlations in the expression of MCMs with Ki67 \[[@B44],[@B47],[@B57]\]. Moreover, several studies have revealed that MCMs are characterized by higher specificity and sensitivity than other conventional proliferative markers \[[@B58],[@B59]\]. Ki-67 is a crucial molecular marker for estimating the progression and prognosis of gliomas \[[@B60],[@B61]\]. Despite the fact that MCMs and Ki67 have a similar expression pattern during many cell cycle phases (G~1~, S, G~2~ and M phases), detailed cell-cycle analysis shows differences between both markers. Ki67 is absent during the early G~1~ phase, whereas MCMs are expressed in the entire G~1~ phase. As such, the degree of tumor cell proliferation may be better reflected by using MCMs.

Kaplan-Meier analysis showed that MCM2, MCM3 and MCM7 can function as an independent prognostic indicator for overall survival (*p* \< 0.05). Our study indicates for the first time that high MCM2 mRNA expression appears to be strongly associated with poor overall survival in high grade glioma. MCM3 expression was found to be up-regulated in glioma and correlated with overall survival in the grade III group. However, MCM3 does not appear to be a predictor of survival in the patients of the grade IV group. Söling *et al*. have also reported results supporting this conclusion \[[@B53]\]. Likewise, MCM2 and MCM3 expression in grade II group does not appear to be a significant predictor, although this might be explained by the limited sample size. Furthermore, we report that MCM7 is correlated with patient outcome in grade II-IV group. Erkan EP *et al.* also report MCM7 was the significant up-regulate gene in GBM samples compared with normal white matter tissues. Moreover, siRNA-mediated knockdown of MCM7 expression reduced GBM cell proliferation and also inhibited tumor growth in both xenograte and orthotopic mouse models of GBM \[[@B56]\].

Conclusions
===========

In conclusion, the results suggest that MCM2, MCM3 and MCM7 play important roles in glioma tumor progression. Most notably, MCM2, MCM3 and MCM7 aberrations in glioma tumors portend a particularly aggressive clinical behavior.
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